SecBot SecBot
PRESS-RELEASE ·Filed Mar 2, 2026

QURE

uniQure Inc.
MIXED
Impact 6/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

While clinical data for AMT-130 remains strong, the FDA's insistence on a costly and time-consuming Phase III trial introduces significant development risk and timeline uncertainty. The strengthened balance sheet supports long-term funding, but investors should monitor the design and feasibility of the future trial, as well as safety developments in AMT-191 and AMT-162.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$10.50
T+0 close · Mar 2, 2026 · via day close
Latest settled
+139.52%
T+60 · $25.15
Vs SPY
+130.20%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 2 $10.50entry
  2. T+1 · 9mo ago −14.00%α −13.09% · $9.03
  3. T+5 · 8mo ago +71.33%α +72.54% · $17.99
  4. T+20 · 8mo ago +40.29%α +48.22% · $14.73
  5. T+60 · 6mo ago +139.52%α +130.20% · $25.15
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

uniQure reported financial results for 2025, showing a revenue decline to $16.1 million and a reduced net loss of $199.0 million, or $3.46 per share, compared to $239.6 million in 2024. The company highlighted clinical progress in its gene therapy pipeline, particularly durable data for AMT-130 in Huntington’s disease, but disclosed that the FDA rejected the use of external controls for approval and mandated a randomized Phase III trial. With $622.5 million in cash, uniQure is funded into 2029.

Key Financial Metrics

Revenue
$16.1M
-40.6% YoY
EPS
$-3.46

Key Facts

  • Revenue decreased to $16.1 million in 2025 from $27.1 million in 2024, driven by lower collaboration and contract manufacturing revenue.
  • Net loss narrowed to $199.0 million ($3.46/share) from $239.6 million ($4.92/share) in 2024.
  • FDA rejected approval pathway for AMT-130 based on single-arm trial with external controls; required a randomized, sham-controlled Phase III study.
  • AMT-130 showed statistically significant 75% slowing in disease progression at 36 months in high-dose patients.
  • Cash, cash equivalents, and investments totaled $622.5 million as of December 31, 2025, up from $367.5 million in 2024.
  • Cash runway now extends into the second half of 2029, supported by $404.2 million raised in public offerings in 2025.
  • Development of AMT-191 paused due to dose-limiting liver toxicities; AMT-162 enrollment remains on hold after a serious adverse event.

Financial Impact

Revenue down $11 million YoY; net loss reduced by $40.6 million; cash increased by $255 million primarily from equity financing.

revenuenet losscash positiondilution

Risk Factors

  • FDA requirement for a sham-surgery controlled trial for AMT-130 increases development cost, timeline, and ethical/enrollment challenges.
  • Clinical holds and safety concerns in AMT-191 and AMT-162 could delay or derail other pipeline programs.
  • Dilution risk from prior share issuances (11.8M shares + 0.5M pre-funded warrants) may weigh on shareholder sentiment despite improved cash position.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3247245

Track record

38 reports on QURE

Performance horizon

6 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +27.15% at T+20 after the Jul 29, 2026 report. 8 of 11 went positive at some point.

Filters
  1. Nov 6, 202610d ago 144 Neutral 2/10 Entry $22.79 to $22.71 Now $21.88 −3.99% ▼ −0.35% +0.02% vs SPY
  2. Nov 4, 202612d ago 8-K Bullish 7/10 No price data
  3. Nov 4, 202612d ago Press Release Neutral 6/10 Entry $23.03 to $21.01 Now $21.88 −4.99% ▼ −8.77% −4.36% vs SPY
  4. Nov 2, 202614d ago 8-K Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
  5. Nov 2, 202614d ago Press Release Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
  6. Oct 16, 20264w ago SC 13G/A Neutral 3/10 Entry $21.78 to $22.20 Now $21.88 +0.46% ▲ +1.93% +1.51% vs SPY
  7. Sep 2, 202610w ago 8-K Bullish 7/10 Entry $46.23 to $44.86 Now $21.88 −52.67% ▼ −2.96% −4.01% vs SPY
  8. Jul 29, 202615w ago 8-K Bullish 8/10 Entry $40.07 to $42.19 Now $21.88 −45.40% ▲ +5.29% +3.61% vs SPY
  9. Jul 7, 202619w ago Insider Cluster Bearish 5/10 Entry $41.41 to $43.49 Now $21.88 +47.16% ▼ −5.02% −5.33% vs SPY
  10. Jul 2, 202619w ago Insider Cluster Bearish 4/10 Entry $41.81 to $41.36 Now $21.88 +47.67% ▲ +1.08% +1.95% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (11h 41m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 2, 2026